Skeletal maturity was not accelerated by treatment with recombinant growth hormone ( hGH ) .
Adverse effects were minimally reported .
There is little evidence of serious short-term adverse effects in these trials , but they are underpowered to detect rare adverse effects .
REVIEW ER 'S CONCLUSIONS Recombinant human growth hormone ( hGH ) doses between 0.3 - 0.375 mg/kg/wk increase short-term growth in girls with Turner Syndrome ( TS ) by approximately 3 cm in the first year of treatment and by approximately 2 cm per year after 2 years of treatment .
There is little evidence on the effects of hGH on final height .
BACKGROUND Turner syndrome ( TS ) affects about one in 1,500 to 2,500 live-born females .
One of the most prevalent and salient features of the syndrome is extremely short stature .
Untreated women are approximately 20 - 21 cm shorter than normal women within their respective population s. Recombinant human growth hormone ( hGH ) has been used to increase growth and final height in women who have Turner syndrome .
OBJECTIVES To assess the effects of recombinant growth hormone on short-term growth and final height in children and adolescents with Turner syndrome .
Growth hormone therapy in Turner's syndrome: one versus two daily injections.
In 44 girls with Turner 's syndrome , aged 4.0 - 15.3 yr , the effects of biosynthetic GH ( 25 U/m2.week ) given as once daily or twice daily injections were compared . During 1 yr of treatment , the growth rate increased similarly by 3.5 + /- 1.3 cm/yr in the once daily group and 2.7 + /- 1.8 cm/yr in the twice daily group . Although pretreatment height velocity was negatively related to age , the increase in height velocity during therapy was not . The mean progression in bone age ( TW2-RUS method ) , during therapy was 1.3 yr in both groups . No significant change in the median insulin secretory response to an oral glucose tolerance test was found . Serum cholesterol and triglyceride concentrations did not change significantly throughout the study in either treatment group . Thyroid hormone concentrations remained within normal limits . Normal increments in left ventricular wall thickness and left ventricular mass for age and body surface were observed after 1 yr of GH treatment . We conclude that division of the daily GH dose given to Turner 's syndrome patients into two injections does not result in either a significantly different growth response or different side-effects from once daily treatment during the first year of therapy
Skeletal maturity was not accelerated by treatment with recombinant growth hormone ( hGH ) .
Adverse effects were minimally reported .
There is little evidence of serious short-term adverse effects in these trials , but they are underpowered to detect rare adverse effects .
REVIEW ER 'S CONCLUSIONS Recombinant human growth hormone ( hGH ) doses between 0.3 - 0.375 mg/kg/wk increase short-term growth in girls with Turner Syndrome ( TS ) by approximately 3 cm in the first year of treatment and by approximately 2 cm per year after 2 years of treatment .
There is little evidence on the effects of hGH on final height .
BACKGROUND Turner syndrome ( TS ) affects about one in 1,500 to 2,500 live-born females .
One of the most prevalent and salient features of the syndrome is extremely short stature .
Untreated women are approximately 20 - 21 cm shorter than normal women within their respective population s. Recombinant human growth hormone ( hGH ) has been used to increase growth and final height in women who have Turner syndrome .
OBJECTIVES To assess the effects of recombinant growth hormone on short-term growth and final height in children and adolescents with Turner syndrome .